A Phase 3 interventional study of Baricitinib in Atopic Dermatitis, sponsored by Eli Lilly and Company. Terminated at 74 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-08.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing baricitinib in Dermatitis, Atopic — 1 open to participants now, 1 under way, none of them phase 3. baricitinib · Dermatitis, Atopic.
Among the 11 studies testing baricitinib in Dermatitis, Atopic, this one is the 7th largest by enrollment, is one of 5 that started in 2018, is one of 8 in phase 3, and was the 7th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →1 of the 11 studies testing baricitinib in Dermatitis, Atopic is open now, in 1 country. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12–120
By country, each count listing its studies:
baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 5 started in 2018.
This study's enrollment of 374 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 440 across the 11 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
30 studies in Dermatitis, Atopic by Eli Lilly and Company: 1 open now, 2 under way, 2 of them phase 3. Of 28 finished, 25 (89%) have results posted.
Among the 30 studies in Dermatitis, Atopic by Eli Lilly and Company, this one is the 11th largest by enrollment, is one of 7 that started in 2018, is one of 21 in phase 3, and was the 9th registered.
Eli Lilly and Company’s Dermatitis, Atopic studies by the year they started, since 2013.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing baricitinib in Dermatitis, Atopic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 30 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
This open-label study will evaluate the long-term efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis (AD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have participated in Study JAIW (NCT03435081), and meet specific completion requirements for that study, and do not meet any of the following Exclusions:
OR
Inclusion Criteria:
Have moderate to severe AD, including all of the following:
Exclusion Criteria:
Have been treated with the following therapies:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open-label 2 mg baricitinib administered orally once daily (QD) to participants who randomized to placebo in the originating study (JAIW).
Drug: Baricitinib
Open-label 2 mg baricitinib administered orally QD to participants who randomized to 1 mg baricitinib in the originating study (JAIW).
Drug: Baricitinib
Open-label 2 mg baricitinib administered orally QD to participants who randomized to 2 mg baricitinib in the originating study (JAIW).
Drug: Baricitinib
Participants were directly enrolled to receive open-label 2 mg baricitinib orally QD.
Drug: Baricitinib
Administered orally
Also known as: LY3009104
Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75)
The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score. The results were analyzed using non-responder imputation (NRI). All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as EASI75.
Time frame: Week 16
Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1
The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. The results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as IGA 0/1.
Time frame: Week 16
Percentage of Participants Achieving a Body Surface Area (BSA) of ≤3%
The BSA affected by AD will be assessed for 4 separate body regions: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region will be assessed for disease extent ranging from 0% to 100% involvement. BSA was calculated using the participant's palm using the 1% rule, 1 palm was equivalent to 1% with estimates of the number of palms it takes to cover the affected AD area. Maximum number of palms were 10 palms for head and neck (10%), 20 palms for upper extremities (20%), 30 palms for trunk, including axilla and groin (30%), 40 palms for lower extremities, including buttocks (40%). Percent of BSA for a body region was calculated as = total number of palms in a body region \* % surface area equivalent to 1 palm. Overall percent BSA of all 4 body regions ranges from 0% to 100 % with higher values representing greater severity of AD.
Time frame: Week 16
Percentage of Participants Achieving a ≥4-Point Improvement in Itch Numeric Rating Scale (NRS)
The NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours.
Time frame: Week 16
Eligible participants (nonresponder/partial responder: completed at least 16 weeks of treatment; responder: completed the full treatment period) from originating study JAIW (NCT03435081) enrolled into Open-label Treatment Period of JAIX \[lasting from Week 0 (baseline through Week 200) or early termination visit\]. Participants enrolled directly into Protocol Addendum I4V-MC-JAIX (2) without first completing at least 16 weeks of treatment in originating study JAIW.
| Milestone | Placebo/Baricitinib 2-milligram (mg) | Baricitinib 1-mg/Baricitinib 2-mg | Baricitinib 2-mg/Baricitinib 2-mg | Baricitinib 2-mg Open-Label Addendum |
|---|---|---|---|---|
| Started | 117 | 119 | 108 | 30 |
| Received at least one dose of study drug | 117 | 119 | 108 | 30 |
| Completed | 0 | 1 | 0 | 0 |
| Not completed | 117 | 118 | 108 | 30 |
| Withdrew: Adverse event | 6 | 5 | 3 | 0 |
| Withdrew: Lack of efficacy | 34 | 52 | 37 | 2 |
| Withdrew: Death | 0 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 16 | 4 | 12 | 3 |
| Withdrew: Sponsor decision | 38 | 31 | 35 | 18 |
| Withdrew: Withdrawal by subject | 19 | 21 | 18 | 7 |
| Withdrew: Physician decision | 3 | 2 | 1 | 0 |
| Withdrew: Pregnancy | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 2 | 0 |
The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score. The results were analyzed using non-responder imputation (NRI). All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as EASI75.
| percentage of participants | Placebo/Baricitinib 2-mg | Baricitinib 1-mg/Baricitinib 2-mg | Baricitinib 2-mg/Baricitinib 2-mg | Baricitinib 2-mg Open-Label Addendum |
|---|---|---|---|---|
| Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) | 59.0 | 40.3 | 45.4 | 50.0 |
The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. The results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as IGA 0/1.
| percentage of participants | Placebo/Baricitinib 2-mg | Baricitinib 1-mg/Baricitinib 2-mg | Baricitinib 2-mg/Baricitinib 2-mg | Baricitinib 2-mg Open-Label Addendum |
|---|---|---|---|---|
| Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 | 44.4 | 18.5 | 29.6 | 40.0 |
The BSA affected by AD will be assessed for 4 separate body regions: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region will be assessed for disease extent ranging from 0% to 100% involvement. BSA was calculated using the participant's palm using the 1% rule, 1 palm was equivalent to 1% with estimates of the number of palms it takes to cover the affected AD area. Maximum number of palms were 10 palms for head and neck (10%), 20 palms for upper extremities (20%), 30 palms for trunk, including axilla and groin (30%), 40 palms for lower extremities, including buttocks (40%). Percent of BSA for a body region was calculated as = total number of palms in a body region \* % surface area equivalent to 1 palm. Overall percent BSA of all 4 body regions ranges from 0% to 100 % with higher values representing greater severity of AD.
| percentage of participants | Placebo/Baricitinib 2-mg | Baricitinib 1-mg/Baricitinib 2-mg | Baricitinib 2-mg/Baricitinib 2-mg | Baricitinib 2-mg Open-Label Addendum |
|---|---|---|---|---|
| Percentage of Participants Achieving a Body Surface Area (BSA) of ≤3% | 39.3 | 21.8 | 35.2 | 43.3 |
The NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours.
| percentage of participants | Placebo/Baricitinib 2-mg | Baricitinib 1-mg/Baricitinib 2-mg | Baricitinib 2-mg/Baricitinib 2-mg | Baricitinib 2-mg Open-Label Addendum |
|---|---|---|---|---|
| Percentage of Participants Achieving a ≥4-Point Improvement in Itch Numeric Rating Scale (NRS) | 41.9 | 29.4 | 30.6 | 26.7 |
Collected over Baseline to Follow-up (Up to 204 Weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo/Baricitinib 2-mg | 0/117 (0%) | 8/117 (6.8%) | 35/117 (29.9%) |
| Baricitinib 1-mg/Baricitinib 2-mg | 2/119 (1.7%) | 8/119 (6.7%) | 22/119 (18.5%) |
| Baricitinib 2-mg/Baricitinib 2-mg | 0/108 (0%) | 10/108 (9.3%) | 28/108 (25.9%) |
| Baricitinib 2-mg Open-Label Addendum | 0/29 (0%) | 0/29 (0%) | 2/29 (6.9%) |
| Event | Placebo/Baricitinib 2-mg | Baricitinib 1-mg/Baricitinib 2-mg | Baricitinib 2-mg/Baricitinib 2-mg | Baricitinib 2-mg Open-Label Addendum |
|---|---|---|---|---|
| Myocardial infarctionCardiac disorders | 0/117 | 2/119 | 0/108 | 0/29 |
| LymphadenopathyBlood and lymphatic system disorders | 0/117 | 0/119 | 1/108 | 0/29 |
| CellulitisInfections and infestations | 0/117 | 1/119 | 1/108 | 0/29 |
| Graft infectionInfections and infestations | 0/117 | 0/119 | 1/108 | 0/29 |
| Pneumonia aspirationInfections and infestations | 0/117 | 0/119 | 1/108 | 0/29 |
| Streptococcal abscessInfections and infestations | 0/117 | 0/119 | 1/108 | 0/29 |
| Wound infectionInfections and infestations | 0/117 | 0/119 | 1/108 | 0/29 |
| Injury cornealInjury, poisoning and procedural complications | 0/117 | 0/119 | 1/108 | 0/29 |
| Vascular graft thrombosisInjury, poisoning and procedural complications | 0/117 | 0/119 | 1/108 | 0/29 |
| Cutaneous t-cell lymphoma stage ivNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/117 | 0/119 | 1/108 | 0/29 |
| Event | Placebo/Baricitinib 2-mg | Baricitinib 1-mg/Baricitinib 2-mg | Baricitinib 2-mg/Baricitinib 2-mg | Baricitinib 2-mg Open-Label Addendum |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 12/117 | 8/119 | 11/108 | 0/29 |
| NasopharyngitisInfections and infestations | 10/117 | 9/119 | 7/108 | 0/29 |
| Covid-19Infections and infestations | 9/117 | 3/119 | 5/108 | 1/29 |
| HeadacheNervous system disorders | 8/117 | 0/119 | 1/108 | 0/29 |
| Urinary tract infectionInfections and infestations | 7/117 | 6/119 | 7/108 | 1/29 |
| AcneSkin and subcutaneous tissue disorders | 6/117 | 1/119 | 1/108 | 0/29 |
Modified intent-to-treat (mITT) population included all participants who received at least one dose of study drug.
| Age, Continuous(years) | Placebo/Baricitinib 2-mg | Baricitinib 1-mg/Baricitinib 2-mg | Baricitinib 2-mg/Baricitinib 2-mg | Baricitinib 2-mg Open-Label Addendum | Total |
|---|---|---|---|---|---|
| Mean | 39.90 ± 16.87 | 40.70 ± 16.86 | 39.30 ± 15.05 | 43.80 ± 17.67 | 40.30 ± 16.41 |
| Sex: Female, Male(Participants) | Placebo/Baricitinib 2-mg | Baricitinib 1-mg/Baricitinib 2-mg | Baricitinib 2-mg/Baricitinib 2-mg | Baricitinib 2-mg Open-Label Addendum | Total |
|---|---|---|---|---|---|
| Female | 55 | 60 | 57 | 16 | 188 |
| Male | 62 | 59 | 51 | 14 | 186 |
| Ethnicity (NIH/OMB)(Participants) | Placebo/Baricitinib 2-mg | Baricitinib 1-mg/Baricitinib 2-mg | Baricitinib 2-mg/Baricitinib 2-mg | Baricitinib 2-mg Open-Label Addendum | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 17 | 13 | 19 | 10 | 59 |
| Not Hispanic or Latino | 97 | 105 | 87 | 20 | 309 |
| Unknown or Not Reported | 3 | 1 | 2 | 0 | 6 |
| Race (NIH/OMB)(Participants) | Placebo/Baricitinib 2-mg | Baricitinib 1-mg/Baricitinib 2-mg | Baricitinib 2-mg/Baricitinib 2-mg | Baricitinib 2-mg Open-Label Addendum | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 2 | 2 | 0 | 6 |
| Asian | 27 | 24 | 19 | 4 | 74 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 20 | 15 | 22 | 4 | 61 |
| White | 61 | 72 | 60 | 22 | 215 |
| More than one race | 6 | 5 | 4 | 0 | 15 |
| Unknown or Not Reported | 1 | 1 | 0 | 0 | 2 |
| Region of Enrollment(participants) | Placebo/Baricitinib 2-mg | Baricitinib 1-mg/Baricitinib 2-mg | Baricitinib 2-mg/Baricitinib 2-mg | Baricitinib 2-mg Open-Label Addendum | Total |
|---|---|---|---|---|---|
| Canada | 36 | 38 | 31 | 0 | 105 |
| United States | 81 | 81 | 77 | 30 | 269 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jun 2018 to primary completion in Oct 2021, 39 months.
Results were first posted in Nov 2022, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib